

















ARTICLE OPEN



CHRONIC LYMPHOCYTIC LEUKEMIA

The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in *SF3B1*-mutated chronic lymphocytic leukemia

Daniel Hägerstrand ^{1,19}, Blaž Oder ^{1,19}, Diego Cortese¹, Ying Qu¹, Amrei Binzer-Panchal ¹, Cecilia Österholm¹, Teresa Del Peso Santos¹, Leily Rabbani¹, Hassan Foroughi Asl¹, Aron Skaftason¹, Viktor Ljungström², August Lundholm¹, Maria Koutroumani³, Zahra Haider¹, Cecilia Jylhä^{1,4}, John Mollstedt¹, Larry Mansouri¹, Karla Plevova^{5,6,7}, Andreas Agathangelidis ^{3,8}, Lydia Scarfò ^{9,10}, Marine Armand ¹¹, Alice F. Muggen¹², Neil E. Kay ^{13,14}, Tait Shanafelt¹⁵, Davide Rossi¹⁶, Lukas M. Orre ¹⁷, Sarka Pospisilova ^{5,6,7}, Konstantin Barylyuk ¹⁷, Frederic Davi¹¹, Mattias Vesterlund ¹⁷, Anton W. Langerak ¹², Janne Lehtiö ¹⁷, Paolo Ghia ^{9,10}, Kostas Stamatopoulos ^{1,3,18}, Lesley-Ann Sutton¹ and Richard Rosenquist ^{1,4}✉

© The Author(s) 2024

SF3B1 mutations are recurrent in chronic lymphocytic leukemia (CLL), particularly enriched in clinically aggressive stereotyped subset #2. To investigate their impact, we conducted RNA-sequencing of 18 *SF3B1*^{MUT} and 17 *SF3B1*^{WT} subset #2 cases and identified 80 significant alternative splicing events (ASEs). Notable ASEs concerned exon inclusion in the non-canonical BAF (ncBAF) chromatin remodeling complex subunit, *BRD9*, and splice variants in eight additional ncBAF complex interactors. Long-read RNA-sequencing confirmed the presence of splice variants, and extended analysis of 139 CLL cases corroborated their association with *SF3B1* mutations. Overexpression of *SF3B1*^{K700E} induced exon inclusion in *BRD9*, resulting in a novel splice isoform with an alternative C-terminus. Protein interactome analysis of the *BRD9* splice isoform revealed augmented ncBAF complex interaction, while exhibiting decreased binding of auxiliary proteins, including SPEN, BRCA2, and CHD9. Additionally, integrative multi-omics analysis identified a ncBAF complex-bound gene quartet on chromosome 1 with higher expression levels and more accessible chromatin in *SF3B1*^{MUT} CLL. Finally, Cancer Dependency Map analysis and *BRD9* inhibition displayed *BRD9* dependency and sensitivity in cell lines and primary CLL cells. In conclusion, spliceosome dysregulation caused by *SF3B1* mutations leads to multiple ASEs and an altered ncBAF complex interactome, highlighting a novel pathobiological mechanism in *SF3B1*^{MUT} CLL.

Leukemia; <https://doi.org/10.1038/s41375-024-02379-4>

INTRODUCTION

Pre-mRNA splicing is mediated by the spliceosome, a large ribonucleoprotein complex composed of five small nuclear ribonucleoproteins (snRNPs), each containing a small nuclear RNA (snRNA) – U1, U2, U4, U5, or U6. During splicing, the catalytic core component Splicing Factor 3b Subunit 1 (SF3B1) interacts with U1 and U2 to recognize 3' and 5' exon-intron boundary splice site motifs [1].

Recurrent *SF3B1* mutations have been reported in various cancer types, including chronic lymphocytic leukemia (CLL), and shown to induce altered splicing by alternative branch point usage or cryptic 3' splice site selection [2–4]. *SF3B1* mutations in CLL, particularly within hotspot exons where the most frequent substitution is p.K700E [5], are associated with rapidly progressive disease [6, 7]. These mutations are enriched in patients belonging

¹Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. ²Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. ³Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece. ⁴Clinical Genetics and Genomics, Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden. ⁵Department of Internal Medicine – Hematology and Oncology, Medical Faculty, Masaryk University and University Hospital Brno, Brno, Czech Republic. ⁶Institute of Medical Genetics and Genomics, Medical Faculty, Masaryk University and University Hospital Brno, Brno, Czech Republic. ⁷Central European Institute of Technology, Masaryk University, Brno, Czech Republic. ⁸Department of Biology, School of Science, National and Kapodistrian University of Athens, Athens, Greece. ⁹Università Vita-Salute San Raffaele, Milan, Italy. ¹⁰Division of Experimental Oncology, IRCCS, Ospedale San Raffaele, Milan, Italy. ¹¹Department of Hematology, Hospital Pitie-Salpetriere, Sorbonne University, Paris, France. ¹²Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands. ¹³Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. ¹⁴Department of Immunology, Mayo Clinic, Rochester, USA. ¹⁵Division of Hematology, Department of Medicine, Stanford University Medical Center, Stanford, CA, USA. ¹⁶Department of Hematology, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland. ¹⁷Department of Oncology-Pathology, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden. ¹⁸Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece. ¹⁹These authors contributed equally: Daniel Hägerstrand, Blaž Oder. ✉email: richard.rosenquist@ki.se

Received: 28 March 2024 Revised: 7 August 2024 Accepted: 12 August 2024

Published online: 11 September 2024

to stereotyped subset #2 (up to 45%) [8–10] and associated with poor response to chemoimmunotherapy and short overall survival [8, 11–14]. *SF3B1* mutations are often found at a subclonal level and expand during disease progression [15]. Accordingly, the occurrence of *SF3B1* mutations in early-stage CLL is about 5–10% and above 20% at advanced stages [5–7]. Mutated *SF3B1* in CLL has been associated with dysregulated DNA damage response, telomere dysfunction, increased Notch signaling mediated through a splice variant of *DVL2*, and activation of NF- κ B signaling facilitated by alternative splicing of *MAP3K7* [3, 16]. In a mouse model, isolated *SF3B1* mutations led to cellular senescence, whereas mutated *SF3B1* in combination with *ATM* loss yielded a CLL-like disease in elderly mice [17].

Recently, *SF3B1* mutations in uveal melanoma (UVM), myelodysplastic syndrome (MDS), and CLL were associated with mis-splicing of Bromodomain Containing 9 (*BRD9*), a subunit of the non-canonical BRG1 (SMARCA4) or BRM (SMARCA2) associated factor (ncBAF) chromatin remodeling complex [18]. Functional studies in UVM indicated that correcting such mis-splicing may restore the tumor suppressor role of BRD9 [18]. The combinatorial assembly of BAF complexes, including canonical BAF (cBAF), polybromo-associated BAF (PBAF), and ncBAF varies between tissues, developmental stages, and disease states [19]. The ncBAF complex is defined by the presence of BRD9 and BICRA (also known as GLTSCR1) but shares common subunits with other BAF complex types [19].

We sought to further investigate *SF3B1* mutation-related alternative splicing events (ASEs) in CLL by performing RNA-sequencing (RNA-seq) in a cohort of 100 CLL cases carrying stereotyped B-cell receptors. Initially, we focused on subset #2 where we detected ASEs in several ncBAF complex-related transcripts, including BRD9. Extended analysis of other subset/non-subset cases and CLL cell lines confirmed our initial findings and led to the discovery of a novel BRD9 splice isoform with an alternative C-terminus, which could be induced by overexpression of mutated *SF3B1*. The alternative BRD9 isoform was shown to bind to the ncBAF complex and alter the interaction with auxiliary ncBAF complex proteins. Finally, drug response experiments revealed the sensitivity of both cell lines and primary CLL cells to a BRD9 inhibitor.

MATERIALS AND METHODS

Patient material

One hundred CLL cases carrying stereotyped B-cell receptors, including subsets #1 (n = 25), #2 (n = 35), #3 (n = 5), #4 (n = 14), #5 (n = 4), #6 (n = 4), #7 (n = 4), #59 (n = 1), #99 (n = 4), and #169 (n = 4), diagnosed according to the 2018 ivCLL criteria were evaluated [20]. In subset #2, there were 18 cases with *SF3B1* mutations (*SF3B1*^{MUT}) and 17 cases without *SF3B1* mutations (*SF3B1*^{WT}). Additionally, 7 more *SF3B1*^{MUT} cases were identified in the other subsets (Supplementary Table 1A). Informed consent was obtained according to the Declaration of Helsinki and each corresponding local Ethics Review Committee approved the study.

RNA extraction, library construction, and short-read RNA-sequencing

Peripheral blood was collected and enriched for tumor cells (>95%) by FACS, bead-based sorting, or negative selection using the RosetteSep Human B Cell Enrichment Cocktail (Stemcell Technologies, Vancouver, BC, Canada). Sequencing libraries were constructed from 100 ng of high-quality RNA as assessed by Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) using the TruSeq Stranded Total RNA library preparation kit with ribosomal depletion through Ribo-Zero Gold treatment (Illumina, San Francisco, CA, USA). Libraries were multiplexed and sequenced on an Illumina HiSeq 2500 system using v4 sequencing chemistry and paired-end 125 base pair read length.

Read mapping, processing, alternative splicing, and differential gene expression analyses

FASTQ files were processed using the nf-core/rnaseq v1.0 pipeline with standard parameters [21], and the quality of short-read RNA-seq was

assessed as detailed in Supplementary Information (Supplementary Table 2A, B). rMATS-turbo v4.1.2 was applied to categorize ASEs into the five types (Fig. 1A) and determine their exon inclusion rate referred to as percent spliced in (PSI) [22]. Only ASEs for which at least 80% of cases in a group had a measurable PSI value were retained. For each ASE, a Δ PSI value, i.e., the difference in average PSI values between groups, was calculated. ASEs with a false discovery rate (FDR) \leq 0.01 and $|\Delta$ PSI| \geq 20% were considered significant. DESeq2 v1.38.3 was used to normalize the count data and determine gene expression values [23].

Long-read RNA-sequencing

Direct and PCR-based long-read RNA-seq was performed in the CLL cell line HG3 and CLL patient samples as detailed in Supplementary Information. The quality of the mapped files was examined using NanoComp v1.19.3 (Supplementary Table 2C) [24].

Cell culture

The CLL cell lines MEC1, PCL12, HG3, PGA1, and CII, the AML cell line HNT34, the UVM cell line MEL202, and the HEK293T cell line were propagated as described in Supplementary Information.

Inducible *SF3B1*^{K700E} and *SF3B1*^{WT} CLL cell lines

The CLL cell lines MEC1 and PCL12 were transduced by lentiviral vectors to overexpress *SF3B1*^{K700E} or *SF3B1*^{WT} under the control of a doxycycline-inducible promoter as detailed in Supplementary Information.

PCR analysis of splice variants

Transcript levels were determined by qPCR using the PowerUp SYBR Green Master Mix (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA) on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA) or by PCR using the REDTaq ReadyMix PCR Reaction Mix (Sigma-Aldrich, Merck, Darmstadt, Germany) on a SimpliAmp Thermal Cycler (Applied Biosystems) followed by agarose gel electrophoresis as described in Supplementary Information.

Generation of stable cell lines overexpressing BRD9 splice isoforms

BRD9 splice variants (Supplementary Information Appendix 1) were cloned from the cDNA of the MEC1 cell line and an *SF3B1*^{MUT} case into a lentiviral vector and stably overexpressed in the HEK293T cell line as detailed in Supplementary Information. Control cell lines were transduced with the same viral backbone as empty or overexpressing FLAG-V5-tagged yellow fluorescent protein (YFP).

Co-immunoprecipitation and mass spectrometry analysis


HEK293T cell lines with stable overexpression of FLAG-V5-tagged YFP, the regular and alternative BRD9 isoforms were subjected to nuclear extraction, lysis, V5-tag-based co-immunoprecipitation, and subsequent analysis by mass spectrometry. Further information is provided in Supplementary Information.

Analysis of publicly available data

RNA-seq and proteomic data from the Spanish CLL cohort (CLLE-ES; Supplementary Table 1B), generated within the International Cancer Genome Consortium (ICGC; <http://platform.icgc-argo.org/>), the Cancer Cell Line Encyclopedia (CCLE; <https://sites.broadinstitute.org/ccle/>), The Cancer Genome Atlas (TCGA; <http://www.cbioportal.org/>, Supplementary Table 1C and 7A, B), dbGaP (study accession phs001959.v1.p1), and ProteomeXchange (study accession PXD028936), were retrieved [25–34]. For analysis of BRD9 and histone chromatin binding, ChIP-sequencing (ChIP-seq) data was downloaded from the ENCODE database (<https://www.encodeproject.org/>) for the chronic myeloid leukemia (CML) cell line K562 [35, 36]. Details are provided in Supplementary Information.

Cancer Dependency Map and drug sensitivity database analyses

For the Cancer Dependency Map (DepMap) analysis, the shinyDepMap portal (<https://labsyspharm.shinyapps.io/depmap>) was



queried with cluster size set to large, probability threshold set to 0, mixing ratio (shRNA:CRISPR) set to 20:80, and efficacy threshold set to 1 [37, 38]. The Genomics of Drug Sensitivity in Cancer (GDSC) database (<https://www.cancerrxgene.org>, Supplementary Table 9) was used to retrieve the sensitivity profile for I-BRD9 across 958 cell lines [39].

Assessment of BRD9 drug sensitivity in CLL cell lines and primary CLL cells

Cell lines and primary CLL cells were treated with BRD9 inhibitors/degraders, I-BRD9 (SML1534; Sigma-Aldrich), PROTAC BRD9 Degrader-1 (HY-103632; MedChemExpress, New Jersey, NJ, USA), and dBRD9 Hydrochloride (SML2911; Sigma-Aldrich) [40, 41]. Dose-response analysis and

Fig. 1 Alternative splicing analysis of *SF3B1*-mutated subset #2 CLL. **A** ASE categories, including skipped exon (SE), alternative 3' splice site usage (A3SS), alternative 5' splice site usage (A5SS), mutually exclusive exon usage (MXE), and intron retention (RI). **B** Bar plot displaying numbers of all identified ASEs in the comparison of 18 *SF3B1*^{MUT} and 17 *SF3B1*^{WT} subset #2 cases across different ASE categories. 163,097 ASEs were detected and involved transcripts of 10,437 genes. **C** Volcano plot depicting all identified ASEs in the comparison of *SF3B1*^{MUT} and *SF3B1*^{WT} subset #2 cases. Red dots indicate ASEs that are considered significant ($|\Delta\text{PSI}| \geq 20\%$ and $\text{FDR} \leq 0.01$; 80 ASEs). **D** Bar plot displaying numbers of significant ASEs in the comparison of *SF3B1*^{MUT} and *SF3B1*^{WT} subset #2 cases across different ASE categories. 80 ASEs were considered significant and involved transcripts of 62 genes. **E** Heatmap illustrating the individual PSI values for the 80 significant ASEs detected in the comparison of *SF3B1*^{MUT} and *SF3B1*^{WT} subset #2 cases. 33 ASEs occurred within the same gene at least twice. ASEs are displayed based on the ASE category. The bar plot to the right of the heatmap shows ΔPSI values. The gene affected by each ASE and the corresponding unique ASE ID are listed. Genes that encode ncBAF complex-interacting proteins are depicted in color. For multiple ASEs per gene, only the top ASE is colored, while the others are marked with black asterisks. Additional details of these ASEs are provided in Supplementary Table 3A, B. **F** Model of the ncBAF chromatin remodeling complex and previously reported ncBAF complex interactors. Alternatively spliced transcripts identified in *SF3B1*^{MUT} subset #2 CLL that encode ncBAF complex-related proteins are depicted in color. **G** Scattered box plot showing the PSI value distribution, ΔPSI values, and *P* values (Wilcoxon rank-sum test) for significant ncBAF complex-related ASEs identified in the comparison of *SF3B1*^{MUT} and *SF3B1*^{WT} subset #2 cases. The specific ASEs for *ZEB1*, *BRD9*, *PLSCR1*, *TENT4B*, *CXXC1*, *DCAF16*, *UBP1*, *DLST*, and *SERBP1* have the unique ASE IDs *ZEB1*_SE_27141, *BRD9*_SE_53886, *PLSCR1*_SE_92684, *PAPD5*_SE_94061, *CXXC1*_SE_102397, *DCAF16*_SE_4627, *UBP1*_SE_85897, *DLST*_A3SS_2409, and *SERBP1*_A3SS_1321, respectively, in Supplementary Table 3A, B. The boxes represent the median and the interquartile range (IQR), while the whiskers extend to 1.5 times the IQR from the first and third quartiles. ASE: alternative splicing event; WT: wildtype; MUT: mutated; FDR: false discovery rate; PSI: percent spliced in; VAF: variant allele frequency.




Fig. 2 Long-read RNA-sequencing validates the predicted alternative transcripts related to the ncBAF complex in *SF3B1*-mutated CLL. Sashimi plots illustrating the identified ASEs and alternative splicing patterns in four genes that encode ncBAF complex-related proteins in *SF3B1*^{WT} versus *SF3B1*^{MUT} CLL; *ZEB1* and *BRD9* exhibit the top two ASEs in the SE category, while *DLST* and *SERBP1* showcase the top two ASEs in the A3SS category. Sashimi plots for other ncBAF complex-related genes, *PLSCR1*, *TENT4B*, *CXXC1*, *DCAF16*, and *UBP1*, are presented in Supplementary Fig. 3. For each gene, the top two sashimi plots within the gray box illustrate the predicted splice variants in *SF3B1*^{WT} versus *SF3B1*^{MUT} CLL. The colored arc highlights the primary ASE, while lighter arcs represent additional ASEs if present. The gene map indicates the relative location and order of the detected exons in relation to the sequencing results. For each corresponding gene, the lower two sashimi plots show the coverage and splice junction count data from the aligned long-read RNA-seq data from an *SF3B1*^{WT} case (RS24) and an *SF3B1*^{MUT} case (RS55), both belonging to subset #2 CLL. The direction of the genes is arranged from left to right. WT: wildtype; MUT: mutated; PSI: percent spliced in.

assessment of proliferation and apoptosis were conducted as detailed in Supplementary Information.

Statistics

Statistical methods, including tests for normality, variance, differences between groups, multiple testing correction, correlation, clustering, and dose-response curve fitting, were applied as described in Supplementary Information.

RESULTS

SF3B1^{MUT} subset #2 cases display a distinct splicing signature linked to the ncBAF chromatin remodeling complex

Splicing analysis was performed in 18 *SF3B1*^{MUT} and 17 *SF3B1*^{WT} subset #2 cases (Supplementary Table 1A). Of all assessed ASEs (Fig. 1B, Supplementary Table 3A), 80 ASEs in transcripts of 62 genes were considered significant (Fig. 1C, Supplementary

Table 3B; $|\Delta\text{PSI}| \geq 20\%$ and $\text{FDR} \leq 0.01$) 51 (63.8%) and 29 (36.2%) of these had positive and negative ΔPSI values, respectively. Overall, $SF3B1^{\text{MUT}}$ subset #2 cases displayed a higher proportion of positive ΔPSI values (Fig. 1D, Supplementary Fig. 1A) and the observed ASEs segregated $SF3B1^{\text{MUT}}$ from $SF3B1^{\text{WT}}$ subset #2 cases (Fig. 1E). When the analysis was expanded to encompass non-subset #2 subset cases (7 $SF3B1^{\text{MUT}}$ and 58 $SF3B1^{\text{WT}}$), including 39 cases from the poor-prognostic subset #1 and the favorable-prognostic subset #4 [42, 43], the splicing signature of $SF3B1^{\text{MUT}}$ remained distinct compared to $SF3B1^{\text{WT}}$ cases (Supplementary Fig. 1B). BRD9 emerged as particularly interesting as it is a subunit of the ncBAF chromatin remodeling complex [44]. In an extended protein-protein interaction network analysis using BioGRID v4.4 (<https://thebiogrid.org>), eight further ncBAF complex-interacting proteins were identified, ZEB1, PLSCR1, TENT4B (also known as PAPD5), CXXC1, DCAF16, UBP1, DLST, and SERBP1 (Fig. 1F, G, Supplementary Fig. 2A, B, Supplementary Table 4) [45].

Long-read RNA-sequencing validates the alternatively spliced ncBAF complex-related transcripts

Long-read RNA-seq confirmed the presence of the full-length alternatively spliced ncBAF complex-related transcripts (Fig. 2,

Supplementary Fig. 3). We also re-analyzed publicly available long-read RNA-seq data from CLL, including cases published by Tang et al., using FLAIR [26]. Overlapping ASEs, including the ASE in *SERBP1*, were identified in $SF3B1^{\text{MUT}}$ cases, as in our analyses of short-read RNA-seq data (Supplementary Fig. 4A, B, Supplementary Table 5).

Extended analyses of ncBAF complex-related alternative splicing events

We investigated the observed ncBAF complex-related ASEs in the remaining 65 subset cases (Supplementary Table 1A and 3C, D) and identified similar splicing differences in $SF3B1^{\text{MUT}}$ versus $SF3B1^{\text{WT}}$ for *ZEB1*, *BRD9*, *DCAF16*, *DLST*, and *SERBP1* (Supplementary Fig. 1C). Subsequent analysis of RNA-seq data from ICGC CLL-ES [30, 31], including 8 $SF3B1^{\text{MUT}}$ and 66 $SF3B1^{\text{WT}}$ cases (Supplementary Table 1B), identified 85 significant ASEs in transcripts of 71 genes (Supplementary Fig. 5A–G, Supplementary Table 6A, B). A significant overlap was observed between the genes targeted by $SF3B1^{\text{MUT}}$ -related ASEs in the ICGC CLL-ES and subset #2 cases, including *BRD9*, *DLST*, and *SERBP1*. Furthermore, we analyzed a set of 1019 cancer cell lines from CCLE [28], including 4 $SF3B1^{\text{MUT}}$ cell lines, and detected significant exon




Fig. 3 *SF3B1* mutations induce alternative splicing of *BRD9* resulting in a splice isoform with an alternative C-terminus. **A** Scheme illustrating lentiviral constructs for *SF3B1*^{WT} and *SF3B1*^{K700E} overexpression under the control of a DOX-inducible promoter. **B** Bar plots depicting expression levels of endogenous and exogenous *SF3B1* upon overexpression of *SF3B1*^{WT} and *SF3B1*^{K700E} in MEC1 and PCL12 cell lines. The bar plots display the mean values of triplicates with error bars representing the standard deviation. **C** Scheme illustrating the identified ASE in *BRD9* with the regular and alternative splicing pattern. The blue and red boxes illustrate constant and alternative exons, respectively. **D** Increased expression of the alternative *BRD9* transcript upon overexpression of *SF3B1*^{K700E} as compared to *SF3B1*^{WT} in MEC1 and PCL12 cell lines. The checkerboard scheme at the top of the panel illustrates the experimental conditions. The bar plots display the expression levels of *BRD9* transcripts in general (transcripts containing exon 14), the regular *BRD9* transcript (transcripts containing exon 14 followed by exon 16), and the alternative *BRD9* transcript (transcripts containing exon 14 followed by exon 15) as determined by qPCR. Results are normalized on *GAPDH* levels and expressed as fold difference between DOX+ and DOX- conditions with corresponding *P* values (Student's *t*-test). The bar plots display the mean values of experimental triplicates, with error bars representing the standard deviation. **E** Agarose gel electrophoresis images of PCR products spanning from exon 14 to 16 and allowing for exon 15 inclusion show a higher abundance of alternative *BRD9* transcript in *SF3B1*^{K700E} DOX+. For a complete gel image see Supplementary Fig. 13A. **F** Assessment of *BRD9* splice variants in *SF3B1*^{WT} and *SF3B1*^{MUT} CLL, AML, and UVM cell lines. MEC1, PGA1, and HG3 are *SF3B1*^{WT} CLL cell lines, CII an *SF3B1*^{K666E} CLL cell line, HNT34 an *SF3B1*^{K700E} AML cell line, and MEL202 an *SF3B1*^{R625G} UVM cell line. The bar plots display the expression levels of *BRD9* transcripts in general, the regular *BRD9* transcript, and the alternative *BRD9* transcript as determined by qPCR. Results for *BRD9* transcripts in general are normalized on *GAPDH* levels, whereas regular and alternative *BRD9* transcript levels are normalized on levels of *BRD9* transcripts in general and expressed as fold difference between MEC1 and other cell lines with corresponding *P* values (Student's *t*-test). The bar plots display the mean values of experimental triplicates, with error bars representing the standard deviation. **G** Agarose gel electrophoresis image of PCR products spanning from exon 14 to 16 and allowing for exon 15 inclusion shows a higher abundance of alternative *BRD9* transcript in *SF3B1*^{MUT} cell lines. For a complete gel image see Supplementary Fig. 13A. **H** Sashimi plots from the *SF3B1*^{WT} CLL cell line HG3 and the *SF3B1*^{MUT} AML and UVM cell lines, HNT34 and MEL202, respectively, illustrating the alternatively spliced exon 15 in *BRD9*. The plots for HG3 are based on direct long-read RNA-seq, and HNT34 (SRR8616208) and MEL202 (SRR12354765) on short-read RNA-seq. **I** *BRD9* splice isoform expression in *SF3B1*^{WT} and *SF3B1*^{MUT} CLL cell lines determined by isoform-specific antibodies. An antibody specific to the C-terminus of the regular *BRD9* isoform detected a single band in both *SF3B1*^{WT} and *SF3B1*^{MUT} cell lines. Conversely, an antibody targeting a constant epitope within the central part of *BRD9*, detected two bands in the *SF3B1*^{MUT} cell line CII and one band in the *SF3B1*^{WT} cell lines MEC1 and PGA1, corresponding to the regular higher molecular weight *BRD9* isoform and the alternative lower molecular weight *BRD9* isoform. For complete blot images see Supplementary Fig. 13A. WT: wildtype; MUT: mutated; DOX: doxycycline.

usage differences within six of the ncBAF complex-related ASEs identified in the comparison of *SF3B1*^{MUT} and *SF3B1*^{WT} subset #2 cases (Supplementary Fig. 6). Finally, we noted a strong correlation between the RNA-seq-based *SF3B1*^{MUT} variant allele frequency (VAF) and the PSI values for most of the ncBAF complex-related ASEs, both in our subset cases and the ICGC CLLE-ES cases (Supplementary Fig. 7A, B) [30, 31].

Alternative *BRD9* splicing in CLL and other cancer types

The most notable ASE in our analysis concerned exon 15 inclusion in *BRD9*. Consistent with our findings, the analysis of long-read RNA-seq data from Tang et al. [26] showed high exon 15 inclusion in *BRD9* in an *SF3B1*^{MUT} case (PSI of 45.1%) contrasting with low exon inclusion in an *SF3B1*^{WT} case (PSI of 2.6%) (Supplementary Fig. 4C).

Since exon 15 inclusion in *BRD9* has been reported to lead to nonsense-mediated decay and lower transcript levels in UVM and MDS, we sought to investigate *BRD9* gene expression levels in additional cancer types that harbor *SF3B1* mutations [18]. In a re-analysis of the UVM cases from TCGA [27, 29, 33, 34], a significant 0.45-fold gene expression difference was found in *SF3B1*^{MUT} compared to *SF3B1*^{WT} cases (Wilcoxon rank-sum test, *P* < 0.001); however, no significant differences were seen in other cancer types (Supplementary Fig. 8, Supplementary Table 7A, B). Furthermore, no significant differences in *BRD9* gene/protein expression between *SF3B1*^{MUT} and *SF3B1*^{WT} cases were identified in three independent gene expression and one proteomic dataset from CLL (Supplementary Fig. 9A–J).

SF3B1 mutations induce alternative *BRD9* splicing and the formation of a splice isoform with an alternative C-terminus

To explore the role of *SF3B1* mutations in alternative splicing of *BRD9*, we used inducible *SF3B1*^{K700E} and *SF3B1*^{WT} overexpression in the CLL cell lines MEC1 and PCL12 (Fig. 3A–C). Overexpression of *SF3B1*^{K700E} selectively increased the levels of the alternative *BRD9* splice variant (Fig. 3D, E; MEC1 and PCL12, Student's *t*-test, *P* < 0.001 and *P* < 0.001, respectively). The expression of the regular and alternative *BRD9* splice variants was also analyzed in 3 *SF3B1*^{WT} cell lines, MEC1, PGA1, and HG3 (all CLL), and 3 *SF3B1*^{MUT} cell lines, CII (CLL), HNT34 (AML), and MEL202 (UVM).

SF3B1^{MUT} cell lines demonstrated significantly higher expression levels of the alternative *BRD9* splice variant compared to *SF3B1*^{WT} cell lines (Fig. 3F, G). Moreover, analysis of short-read RNA-seq data from 2 *SF3B1*^{MUT} cell lines, HNT34 and MEL202, demonstrated high exon 15 inclusion (PSI of 78.9% and 48.5%, respectively) (Fig. 3H).


Based on the splicing pattern observed in *BRD9*, we anticipated that the alternative splicing yields a *BRD9* isoform with an alternative C-terminus. Using anti-*BRD9* antibodies against different epitopes, we noted that the *SF3B1*^{MUT} CII cell line expressed an isoform shorter than the regular 67 kDa isoform that could only be detected with an antibody specific for the central part of the protein, but not with an antibody specific for the C-terminus of the regular *BRD9* isoform (Fig. 3I). In contrast, the *SF3B1*^{WT} cell lines showed a single 67 kDa band of the regular *BRD9* isoform that could be detected by both antibodies.

Cloning of *BRD9* splice variants and interactome analysis

According to NCBI RefSeq, the inclusion of exon 15 in *BRD9* is predicted to add an alternative C-terminus to *BRD9*, where the regular 89 amino acids in the C-terminus encoded by exons 16 and 17 are exchanged for 45 amino acids encoded by exon 15 (Fig. 4A).

The two *BRD9* splice variants were cloned and overexpressed in the HEK293T cell line by lentiviral transduction (Fig. 4B). Subsequently, their interactomes were investigated by co-immunoprecipitation and mass spectrometry. Both splice isoforms bound to most ncBAF complex subunits (Fig. 4C, Supplementary Table 8A–C). The alternative *BRD9* isoform showed a significantly lower interaction with 33 proteins, including SPEN, BRCA2, ASPM, and CHD9, and a higher interaction with TARBP1 (Fig. 4D). In comparison with 11 previously reported *BRD9* interactors, SPEN, BRCA2, and CHD9 intersected with these auxiliary ncBAF complex proteins (Fig. 4E) [46].

The interaction with BICRA, SMARCA4, and SMARCC1 was recapitulated in independent co-immunoprecipitation experiments (Fig. 4F). In addition, the alternative *BRD9* isoform displayed a higher binding capacity for these ncBAF complex subunits as compared to the regular *BRD9* isoform (Fig. 4G).



A gene quartet on chromosome 1 bound by *BRD9* is highly expressed in *SF3B1*^{MUT} CLL
Comparison between *SF3B1*^{MUT} and *SF3B1*^{WT} subset #2 cases revealed 55 and 22 significantly higher and lower expressed genes in *SF3B1*^{MUT} cases, respectively (Fig. 5A, B; $|\log_2FC| \geq 0.58$ and

FDR < 0.01). Analysis of the chromosomal positions of differentially expressed genes identified four adjacent genes on chromosome 1, *NOL9*, *TAS1R1*, *ZBTB48*, and *KLHL21*, which were upregulated in *SF3B1*^{MUT} subset #2 cases (Fig. 5C). In a similar comparison of RNA-seq data from ICGC CLL-E-S [30, 31] (Supplementary Fig. 10A, B)

Fig. 4 The regular and alternative BRD9 isoforms display different interactomes. **A** Scheme illustrating *BRD9* splice variants and predicted protein isoforms according to NCBI RefSeq (Annotation release GCF_000001405.40-RS_2023_03). The zoom-in view highlights the predicted protein sequence stemming from exon 15 inclusion in *BRD9*. Upon translation of exon 15, a stop codon emerges near the end of the exon, resulting in a shorter splice isoform with an alternative C-terminus. **B** Scheme depicting lentiviral constructs for overexpression of the regular and alternative *BRD9* splice variants. The corresponding DNA and protein sequences are available in Supplementary Information Appendix 1. **C** Heatmap illustrating the detected ncBAF complex subunits upon co-immunoprecipitation and subsequent mass spectrometry analysis with the regular or alternative *BRD9* isoforms stably overexpressed in the HEK293T cell line. The relative protein levels are based on the total number of identified peptide-spectrum matches (PSMs) for the corresponding protein from the mass spectrometry analysis. The ncBAF complex model to the right of the heatmap illustrates that the alternative *BRD9* isoform precipitated a majority of the ncBAF complex subunits. ACTB was not detected among the co-immunoprecipitates. The control cells expressing FLAG-V5-tagged YFP were used. **D** Volcano plot displaying differential interaction analysis of proteins that selectively interacted more with the regular or alternative *BRD9* isoforms (multiple Student's *t*-tests with Benjamini–Hochberg multiple testing correction). The top 5 candidates are highlighted in red. **E** Venn diagram showing a comparison of the significant differentially interacting proteins with the regular or alternative *BRD9* isoforms and *BRD9*-interacting proteins reported by Gaudio et al. [46]. The intersecting proteins are SPEN, BRCA2, and CHD9. **F** Western blot analysis of V5-tag and BICRA co-immunoprecipitates in the HEK293T cell line with stable overexpression of the regular and alternative *BRD9* isoforms. In the V5-tag immunoprecipitations, both overexpressed *BRD9* isoforms precipitated BICRA together with SMARCA4 and SMARCC1. Reciprocal BICRA co-immunoprecipitations precipitated both overexpressed *BRD9* isoforms, SMARCA4 and SMARCC1. The control cells were transduced with an empty lentiviral vector. For complete blot images see Supplementary Fig. 13A. **G** Bar plots showing V5-tag and BICRA co-immunoprecipitation efficiency with *BRD9*, BICRA, SMARCA4, and SMARCC1. Results are expressed as fold differences between the regular and alternative *BRD9* isoforms with corresponding *P* values (Student's *t*-test). The bar plots display the mean values from three repeated experiments, with error bars representing the standard deviation. For detailed quantification and calculation see Supplementary Fig. 13B. PSM: peptide-spectrum matches; FDR: false discovery rate; IP: immunoprecipitation.

and TCGA CLL [29, 33, 34] (Supplementary Fig. 10C–E), we observed an overlap between the 3 datasets, indicating upregulation of *ZBTB48* and *TAS1R1* in *SF3B1^{MUT}* (Fig. 5D). By comparing the differentially expressed genes in *SF3B1^{MUT}* subset #2 cases with published ATAC-seq data of *SF3B1^{MUT}* CLL [47], the gene quartet also exhibited increased chromatin accessibility in *SF3B1^{MUT}* CLL (Fig. 5E). ChIP-seq data of the CML cell line K562 indicated that *BRD9*, *SMARCA4*, and *SMARCC2* can bind to the gene quartet (Fig. 5F). Furthermore, based on the high signal for H3K27ac, H3K4me3, H3K9ac, H3K79me2, and H3K36me3, and the low signal for H3K27me3 and H3K9me3, these genes appear transcriptionally active [35, 36].

***BRD9* displays a selective dependency**

In a DepMap analysis, which assesses gene dependency based on CRISPR and RNA interference data in cancer cell lines [37, 38], *BRD9* appeared to have relatively high selectivity and efficacy (Fig. 5G). In detail, *BRD9* was located together with other known cancer dependencies, including *PIK3R1*, *EZH2*, and *FBXW7*, whereas *SF3B1* had a very high efficacy but low selectivity. Upon functional similarity clustering, *BRD9* clustered with the BAF complex subunit *SMARCD1* and multiple genes from the transcriptional regulator Mediator complex and the Spt-Ada-Gcn5 Acetyltransferase (SAGA) complex (Fig. 5H). Of the included CLL cell lines, the *SF3B1^{MUT}* CII cell line displayed a higher dependency on *BRD9* than the 3 *SF3B1^{WT}* cell lines MEC1, PGA1, and HG3 (Fig. 5I).

***BRD9* inhibition reveals cytotoxic effects in cell lines and primary CLL cells**

The differential sensitivity of *SF3B1^{MUT}* and *SF3B1^{WT}* cell lines towards chemical *BRD9* inhibition was evaluated through exposure to I-*BRD9*, PROTAC *BRD9* Degradere-1, and d*BRD9*. Complete cell killing was achieved exclusively with I-*BRD9* treatment, allowing for the determination of the corresponding half-maximal inhibitory concentration (IC_{50}) values for each cell line (Fig. 6A). The cell lines demonstrated similar sensitivity to I-*BRD9* treatment with no apparent response to PROTAC *BRD9* Degradere-1 and d*BRD9* treatment, except for the *SF3B1^{MUT}* AML HNT34 cell line, which showed sensitivity to all three drugs. Similarly, HEK293T cell lines stably overexpressing regular and alternative *BRD9* isoforms exhibited sensitivity only to I-*BRD9*, with no discernible difference in response between the two conditions (Supplementary Fig. 11).

In a GDSC query assessing I-*BRD9* sensitivity across 958 cell lines, the cell lines susceptible to *BRD9* inhibition were predominantly from hematological malignancies (89% compared to the expected 17%), notably including CLL (Fig. 6B, Supplementary Table 9) [39].

The *SF3B1^{WT}* cell line PGA1 and the *SF3B1^{MUT}* cell lines CII and HNT34 were further assessed for anti-proliferative and pro-apoptotic effects upon treatment with 10 μ M I-*BRD9*, 25 μ M PROTAC *BRD9* Degradere-1, and 25 μ M d*BRD9* through BrdU incorporation (Fig. 6C, D) and Annexin V binding (Fig. 6E, F). The most potent anti-proliferative and pro-apoptotic effects were observed with I-*BRD9*, particularly in the CII cell line (44.9% decrease in proliferating cells, and 38.0% increase in early apoptotic cells compared to control, one-way ANOVA, $P < 0.001$ and $P = 0.017$, respectively). Treatment with PROTAC *BRD9* Degradere-1 yielded pro-apoptotic properties primarily in the HNT34 cell line, while also demonstrating some anti-proliferative effects in the CII and HNT34 cell lines. Apoptosis induction upon treatment with d*BRD9* was observed exclusively in the HNT34 cell line, with no apparent anti-proliferative effects detected across any of the tested cell lines. Comparable results were obtained using cell viability measurements on the same set of cells (Fig. 6G).

Sensitivity to *BRD9* inhibition was also assessed in primary CLL cells. Treatment with I-*BRD9* showed similar IC_{50} values between *SF3B1^{MUT}* and *SF3B1^{WT}* cells (Fig. 7A; mean IC_{50} of 8.7 μ M and 7.7 μ M, respectively), while no response to PROTAC *BRD9* Degradere-1 and d*BRD9* treatment was observed (Supplementary Fig. 12A, B). Furthermore, the same primary CLL cells were examined for induced apoptosis at the same drug concentrations as for cell lines. I-*BRD9* induced comparable pro-apoptotic effects between *SF3B1^{MUT}* and *SF3B1^{WT}* cells (Fig. 7B, C; 16.3% and 12.3% of early apoptotic cells compared to control, Student's *t*-test, $P = 0.019$ and $P = 0.039$, respectively), whereas PROTAC *BRD9* Degradere-1 and d*BRD9* did not induce apoptosis (Supplementary Fig. 12C, D).

DISCUSSION

SF3B1 mutations and spliceosome dysregulation have been associated with a particularly dismal outcome in CLL [3, 5–7, 10, 18, 48]. Here, we report that a prominent feature in *SF3B1^{MUT}* CLL concerns the inclusion of an alternative exon in the ncBAF chromatin remodeling complex subunit *BRD9*, resulting in a novel splice isoform with an alternative C-terminus [49]. Additional

Fig. 5 *BRD9* binds a gene quartet on chromosome 1 and displays selective dependency in DepMap. **A** Volcano plot depicting differentially expressed genes between 18 *SF3B1*^{MUT} and 17 *SF3B1*^{WT} subset #2 cases with 22 downregulated and 55 upregulated genes ($|\log_2FC| \geq 0.58$ and $FDR < 0.01$). **B** Unsupervised clustermap illustrating the distinct clustering of *SF3B1*^{MUT} and *SF3B1*^{WT} subset #2 cases based on differential gene expression. The four neighboring genes, *NOL9*, *TAS1R1*, *ZBTB48*, and *KLHL21*, located on chromosome 1 are depicted in color. The Ward method and the Euclidean metric were employed. **C** Karyoplot of chromosome 1 displaying differentially expressed genes between *SF3B1*^{MUT} and *SF3B1*^{WT} subset #2 cases. Examination of chromosomal positions revealed four neighboring genes, *NOL9*, *TAS1R1*, *ZBTB48*, and *KLHL21*. **D** Venn diagram showing the overlap of genes with differential expression between *SF3B1*^{MUT} and *SF3B1*^{WT} cases in three independent datasets; subset #2 CLL, ICGC CLL-ES [30, 31], and TCGA CLL [29, 33, 34]. For the differential gene expression analyses of the latter two datasets see Supplementary Fig. 10A–E. *ZBTB48* appeared upregulated in all three datasets, while *TAS1R1* in subset #2 CLL and ICGC CLL-ES. **E** Venn diagram showing the overlap of genes with higher expression levels in *SF3B1*^{MUT} subset #2 cases and increased chromatin accessibility in *SF3B1*^{MUT} CLL cases from Beekman et al. [47]. The overlap comprises *NOL9*, *TAS1R1*, *ZBTB48*, and *KLHL21*. **F** Coverage tracks from ChIP-seq data sourced from the ENCODE database [35, 36], based on the CML cell line K562, illustrating the binding of BRD9 and the ncBAF complex subunits SMARCA4 and SMARCC2 to the gene quartet region on chromosome 1. The promoters for these genes appear active based on the signal for H3K27ac, H3K4me3, H3K9ac, and H3K79me2, and transcriptionally active based on the H3K36me3 signal, whereas transcriptional repression is low based on the low signal for H3K27me3 and H3K9me3. **G** Gene essentiality map showing the relationship between efficacy and selectivity of genes in shinyDepMap [37, 38]. *SF3B1* appears as a non-selective dependency with high efficacy, while *BRD9* as a selective dependency with high efficacy. *BRD9* is in the dependency region of *PIK3R1*, *EZH2*, and *FBXW7*. **H** Functional similarity clustering showing a chromatin remodeling dependency cluster connected to the *BRD9* dependency signature in shinyDepMap. *BRD9* clusters with *SMARCD1*, a BAF complex subunit, subunits of the Mediator complex, p300/CBP subunits, and subunits of the SAGA complex. **I** *BRD9* dependency ranking of the 1086 DepMap (22Q2) cell lines. For CLL cell lines, gene effect scores are given within the parenthesis. WT: wildtype; MUT: mutated; FDR: false discovery rate; FC: fold change.

SF3B1^{MUT} cells exist within the cancer cell population [15]. Consistent with this, we observed a strong correlation between PSI values and *SF3B1* VAF.

The potential significance of the multiple identified ASEs in transcripts encoding ncBAF complex-related proteins was examined using nanopore-based long-read RNA-seq, which confirmed many of the ASEs identified in our short-read RNA-seq analysis. Furthermore, they were observed in extended analyses of independent cohorts, showing that aberrant splicing extends beyond subset #2 CLL. On these grounds, the ncBAF complex may be targeted at multiple levels in *SF3B1*^{MUT} CLL beyond *BRD9*. In addition to these alterations, BAF complex subunits *SMARCC1* and *ARID1A* are deleted or mutated in 2% of CLL cases each [51].

The role of BRD9 in oncogenesis appears two-sided since BRD9 has been shown to either drive or suppress cancer phenotypes [18, 52]. The inclusion of exon 15 in *BRD9* occurs in proximity to the DUF3512 domain which is critical for the integrity of the ncBAF complex [18, 52]. In UVM, alternative splicing of *BRD9* in connection to *SF3B1* mutations was reported to decrease BRD9 protein levels due to nonsense-mediated decay [18]. Here, we also established a causative connection between mutated *SF3B1* and alternative splicing of *BRD9*. However, in contrast to UVM, we did not observe notably lower gene/protein expression levels in CLL. Instead, we detected a novel shorter BRD9 splice isoform with an alternative C-terminus caused by the exon 15 inclusion.

In the BRD9 interactome analysis, both BRD9 splice isoforms were found to bind to most subunits of the ncBAF complex, supporting a maintained ncBAF complex interaction capacity of the alternative isoform. Moreover, the alternative BRD9 isoform showed a relatively higher interaction with TARBP1, and a relatively lower interaction with auxiliary factors, including SPEN, BRCA2, ASPM, and CHD9, that are known to interact with BRD9 [46]. *SPEN* has been described to be mutated in CLL and thought to suppress Notch signaling; a de-coupling of the BRD9 interaction with SPEN may potentially lead to a similar outcome [53]. In this context, it is relevant to mention that previously observed alternative splicing of *DVL2* has been linked to increased Notch signaling [3]. We also observed ASEs in *DVL2*, although they did not reach our cut-off. As for the BRCA2 interaction, it may be connected to the previously reported impaired DNA repair observed in *SF3B1*^{MUT} CLL [3]. Regarding differences in the integration of the two BRD9 splice isoforms into the ncBAF complex, co-immunoprecipitation experiments


of BRD9 and BICRA, SMARCA4, and SMARCC1 revealed a higher affinity of the alternative BRD9 isoform to the ncBAF complex subunits.

In an integrative analysis of gene expression, chromatin accessibility, and DNA-protein interactions, we found that differentially expressed genes between *SF3B1*^{MUT} and *SF3B1*^{WT} are associated with an open chromatin structure in a focal region on chromosome 1, bound by BRD9 and the BAF complex subunits SMARCA4 and SMARCC2. Remarkably, the four adjacent genes located in this region, namely *NOL9*, *TAS1R1*, *ZBTB48*, and *KLHL21*, demonstrate higher expression levels in *SF3B1*^{MUT} CLL. Although their role in CLL pathogenesis is currently unknown, *ZBTB48* (also known as *TZAP*) is implicated in telomere maintenance whereby it binds to and shortens telomere length [54]. This is relevant, considering that particularly short telomeres and high telomerase activity have been reported in *SF3B1*^{MUT} and subset #2 patients [55, 56].

Increased BRD9 incorporation into the ncBAF complex has been reported in *SMARCB1*-mutated sarcoma cell lines [52] and demonstrated to induce synthetic lethality in synovial sarcoma and rhabdomyosarcoma cell lines with perturbed *SMARCB1* [44]. On these grounds, BRD9 targeting using PROTAC degraders is currently under investigation in a phase 1 clinical trial (NCT04965753) in patients with advanced synovial sarcoma or advanced *SMARCB1*-loss tumors.

In our BRD9 inhibition experiments, the *SF3B1*^{MUT} CLL and AML cell lines, CII and HNT34, respectively, were sensitive to I-BRD9, both regarding increased apoptosis and decreased proliferation rate. In addition, the PROTAC BRD9 Degradator-1 demonstrated anti-proliferative effects in both CII and HNT34. Furthermore, our DepMap analysis revealed the selective dependency of the CII cell line on *BRD9*, highlighting its critical role as a tumor suppressor. Intriguingly, the co-dependency of *BRD9* with *SMARCD1*, a BAF complex subunit, along with subunits of the Mediator and SAGA complexes, suggests an intricate interplay between chromatin remodeling complexes in CLL pathogenesis. Notably, *MED12*, a Mediator complex subunit, is recurrently mutated in CLL [57], and recent studies indicate crosstalk between the Mediator and BAF complexes [58].

Finally, in extended experiments using primary CLL cells, I-BRD9 treatment elicited comparable responses in *SF3B1*^{MUT} and *SF3B1*^{WT} cells in terms of IC₅₀ values and pro-apoptotic effects. Thus, while treatment of cell lines revealed a distinct association with *SF3B1* mutations, primary CLL cells displayed sensitivity to I-BRD9 treatment independent of *SF3B1* mutation status. This finding



implies a vulnerability to BRD9 inhibition in CLL that warrants further investigation.

In conclusion, we have identified distinct *SF3B1*^{MUT}-related ASEs involving the ncBAF complex and characterized potential upstream and downstream mechanisms of action. These ASEs

impact the ncBAF complex function from multiple vantage points with expected chromatin modulatory effects and subsequently altered gene expression. Our findings suggest functional consequences of *SF3B1* mutations and highlight ncBAF complex subunits as potential targets for therapeutic exploration in CLL.

Fig. 6 BRD9 inhibition exhibits anti-proliferative and pro-apoptotic effects in SF3B1-mutated cell lines. **A** Dose-response analysis of I-BRD9, PROTAC BRD9 Degrader-1, and dBRD9 treatments in 3 *SF3B1*^{WT} cell lines, MEC1, PGA1, and HG3 (all CLL), and 3 *SF3B1*^{MUT} cell lines, CII (CLL), HNT34 (AML), and MEL202 (UVM). The cell lines were treated with drug concentrations ranging from 0.001 to 50 μ M for 3 days, and cell viability was determined by CellTiter-Glo 2.0. Complete cell killing was exclusively observed with I-BRD9 treatment, allowing for the determination of corresponding IC₅₀ values for each cell line. The HNT34 cell line exhibited sensitivity to all three drugs, thereby allowing for the determination of IC₅₀ values for all conditions. Dose-response curves are shown with 95% confidence intervals, while individual dots display the mean values of triplicates, with error bars representing the standard deviation. **B** I-BRD9 sensitivity profile in 958 cancer cell lines from GDSC [39]. **C** Assessment of proliferation in an *SF3B1*^{WT} cell line, PGA1, and *SF3B1*^{MUT} cell lines, CII and HNT34, upon treatment with 10 μ M I-BRD9, 25 μ M PROTAC BRD9 Degrader-1, or 25 μ M dBRD9. Cell lines were treated for 3 days with a 5-hour exposure to BrdU at the end, and proliferation was quantified by flow cytometry, measured as BrdU+ cells. Vehicle (DMSO) was used as the negative control for drug treatment, while cells not exposed to BrdU served as the negative control to assess the specificity of the anti-BrdU antibody. The upper left quadrants (BrdU+ cells) in the density plots represent the percentages of proliferating cells. **D** Bar plot displaying differences in the percentages of proliferating cells compared to negative controls with corresponding *P* values (one-way ANOVA). The bar plot displays the mean values from two repeated experiments, with error bars representing the standard deviation. **E** Assessment of apoptosis in the same cell lines and the identical samples as in (C). Treatment with 5 μ M Camptothecin and vehicle (DMSO) were used as the positive and negative controls, respectively. Apoptosis was evaluated by Annexin V/PI staining and subsequent flow cytometry analysis. The lower left (Annexin V-/PI- cells), upper left (Annexin V+/PI- cells), and upper right (Annexin V+/PI+ cells) quadrants in the density plots represent the percentages of viable, early apoptotic, and late apoptotic cells, respectively. **F** Stacked bar plot displaying differences in the percentages of viable, early apoptotic, and late apoptotic cells compared to negative controls with corresponding *P* values (one-way ANOVA). The bar plot displays the mean values from two repeated experiments, with error bars representing the standard deviation. **G** Bar plot showing cell viability differences as determined by CellTiter-Glo 2.0 in the same cell lines under the same experimental conditions as in panels (C, E) with corresponding *P* values (one-way ANOVA). The bar plot displays the mean values from two repeated experiments in triplicates, with error bars representing the standard deviation. WT: wildtype; MUT: mutated; IC₅₀: half-maximal inhibitory concentration; RLU: relative luminescence unit.




Fig. 7 BRD9 inhibition induces potent pro-apoptotic effects in primary CLL cells. **A** Dose-response analysis of I-BRD9 treatment in 3 *SF3B1*^{WT} (SKL48, SKL152, SKL53) and 3 *SF3B1*^{MUT} (SKL147, SKL47, SKL157) primary CLL cell samples. The cell lines were treated with drug concentrations ranging from 0.001 to 50 μ M for 2 days, and cell viability was determined by CellTiter-Glo 2.0. Dose-response curves are shown with 95% confidence intervals, while individual dots display the mean values of triplicates, with error bars representing the standard deviation. **B** Stacked density plots showing apoptosis assessment in the same primary CLL cell samples as in (A). Treatment with 5 μ M Camptothecin and vehicle (DMSO) were used as the positive and negative controls, respectively. Apoptosis was evaluated by Annexin V/PI staining and subsequent flow cytometry analysis. The lower left (Annexin V-/PI- cells), upper left (Annexin V+/PI- cells), and upper right (Annexin V+/PI+ cells) quadrants in the density plots represent the percentages of viable, early apoptotic, and late apoptotic cells, respectively. **C** Stacked bar plot displaying differences in the percentages of viable, early apoptotic, and late apoptotic cells compared to negative controls with corresponding *P* values (Student's *t*-test). The bar plot displays the mean values, with error bars representing the standard deviation. WT: wildtype; MUT: mutated; IC₅₀: half-maximal inhibitory concentration; RLU: relative luminescence unit.

DATA AVAILABILITY

The short-read and long-read RNA-sequencing data, including raw and aligned files, have been deposited at the European Genome-phenome Archive under the study accession EGAS00001006771. The direct long-read RNA-sequencing data of the CLL cell line HG3 have been deposited at Figshare with <https://doi.org/10.17044/scilifelab.21694799>.

REFERENCES

- Wahl MC, Will CL, Lührmann R. The Spliceosome: design principles of a dynamic RNP machine. *Cell*. 2009;136:701–18.
- DeBoever C, Ghia EM, Shepard PJ, Rassenti L, Barrett CL, Jepsen K, et al. Transcriptome sequencing reveals potential mechanism of cryptic 3' splice site selection in *SF3B1*-mutated cancers. *PLoS Comput Biol*. 2015;11:e1004105.
- Wang L, Brooks AN, Fan J, Wan Y, Gambe R, Li S, et al. Transcriptomic characterization of *SF3B1* mutation reveals its pleiotropic effects in chronic lymphocytic leukemia. *Cancer Cell*. 2016;30:750–63.
- Mansouri L, Thorvaldsdottir B, Sutton L-A, Karakatsoulis G, Meggendorfer M, Parker H, et al. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. *Leukemia*. 2023;37:339–47.
- Quesada V, Conde L, Villamor N, Ordóñez GR, Jares P, Bassaganyas L, et al. Exome sequencing identifies recurrent mutations of the splicing factor *SF3B1* gene in chronic lymphocytic leukemia. *Nat Genet*. 2012;44:47–52.
- Rossi D, Brusca A, Spina V, Rasi S, Khatibian H, Messina M, et al. Mutations of the *SF3B1* splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. *Blood*. 2011;118:6904–8.
- Baliakas P, Hadzidimitriou A, Sutton L-A, Rossi D, Minga E, Villamor N, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. *Leukemia*. 2015;29:329–36.
- Strefford JC, Sutton L-A, Baliakas P, Agathangelidis A, Malčíková J, Plevova K, et al. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of *SF3B1* and subset #2. *Leukemia*. 2013;27:2196–9.

9. Rossi D, Spina V, Bomben R, Rasi S, Dal-Bo M, Brusca G, et al. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. *Blood*. 2013;121:4902–5.
10. Sutton L-A, Young E, Baliakas P, Hadzidimitriou A, Moysiadis T, Plevova K, et al. Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. *Haematologica*. 2016;101:959–67.
11. Tobin G, Thunberg U, Johnson A, Thörn I, Söderberg O, Hultdin M, et al. Somatic mutations in VH3-21 genes characterize a new subset of chronic lymphocytic leukemia. *Blood*. 2002;99:2262–4.
12. Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton L-A, Minga E, Tsanousa A, et al. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. *Blood*. 2015;125:856–9.
13. Baliakas P, Mattsson M, Hadzidimitriou A, Minga E, Agathangelidis A, Sutton L-A, et al. No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy. *Haematologica*. 2018;103:e158–61.
14. Jaramillo S, Agathangelidis A, Schneider C, Bahlo J, Robrecht S, Tausch E, et al. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). *Haematologica*. 2020;105:2598–607.
15. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. *Cell*. 2013;152:714–26.
16. López-Oreja I, Gohr A, Playa-Albinyana H, Giró A, Arenas F, Higashi M, et al. SF3B1 mutation-mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia. *Life Sci Alliance*. 2023;6:e202301955.
17. Yin S, Gambe RG, Sun J, Martinez AZ, Cartun ZJ, Regis FFD, et al. A murine model of chronic lymphocytic leukemia based on B cell-restricted expression of SF3B1 mutation and Atm deletion. *Cancer Cell*. 2019;35:283–96.e5.
18. Inoue D, Chew G-L, Liu B, Michel BC, Pangallo J, D'Avino AR, et al. Spliceosomal disruption of the non-canonical BAF complex in cancer. *Nature*. 2019;574:432–6.
19. Wanior M, Krämer A, Knapp S, Joergers AC. Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy. *Oncogene*. 2021;40:3637–54.
20. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. *Blood*. 2018;131:2745–60.
21. Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, et al. The nf-core framework for community-curated bioinformatics pipelines. *Nat Biotechnol*. 2020;38:276–8.
22. Shen S, Park JW, Lu Z, Lin L, Henry MD, Wu YN, et al. rMATS: Robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. *Proc Natl Acad Sci*. 2014;111:E5593–601.
23. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol*. 2014;15:550.
24. De Coster W, D'Hert S, Schultz DT, Cruys M, Van Broeckhoven C. NanoPack: visualizing and processing long-read sequencing data. *Bioinformatics*. 2018;34:2666–9.
25. Mailman MD, Feolo M, Jin Y, Kimura M, Tryka K, Bagoutdinov R, et al. The NCBI dbGaP database of genotypes and phenotypes. *Nat Genet*. 2007;39:1181–6.
26. Tang AD, Soulette CM, van Baren MJ, Hart K, Hrabeta-Robinson E, Wu CJ, et al. Full-length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia reveals downregulation of retained introns. *Nat Commun*. 2020;11:1438.
27. Aaltonen LA, Abascal F, Abeshouse A, Aburatani H, Adams DJ, Agrawal N, et al. Pan-cancer analysis of whole genomes. *Nature*. 2020;578:82–93.
28. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature*. 2012;483:603–7.
29. Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, et al. Mutations driving CLL and their evolution in progression and relapse. *Nature*. 2015;526:525–30.
30. Zhang J, Bajari R, Andric D, Gerthoffert F, Lepsa A, Nahal-Bose H, et al. The International Cancer Genome Consortium Data Portal. *Nat Biotechnol*. 2019;37:367–9.
31. Ramsay AJ, Martínez-Trillos A, Jares P, Rodríguez D, Kwarciak A, Quesada V. Next-generation sequencing reveals the secrets of the chronic lymphocytic leukemia genome. *Clin Transl Oncol*. 2013;15:3–8.
32. Herbst SA, Vesterlund M, Helmboldt AJ, Jafari R, Siavelis I, Stahl M, et al. Proteogenomics refines the molecular classification of chronic lymphocytic leukemia. *Nat Commun*. 2022;13:6226.
33. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal*. 2013;6:1–1.
34. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov*. 2012;2:401–4.
35. Luo Y, Hitz BC, Gabdank I, Hilton JA, Kagda MS, Lam B, et al. New developments on the Encyclopedia of DNA Elements (ENCODE) data portal. *Nucleic Acids Res*. 2020;48:D882–9.
36. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. *Nature*. 2012;489:57–74.
37. Shimada K, Bachman JA, Muhlich JL, Mitchison TJ. shinyDepMap, a tool to identify targetable cancer genes and their functional connections from Cancer Dependency Map data. *Elife*. 2021;10:1–20.
38. Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a Cancer Dependency Map. *Cell*. 2017;170:564–76.e16.
39. Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. *Nucleic Acids Res*. 2012;41:D955–61.
40. Remillard D, Buckley DL, Paulk J, Brien GL, Sonnett M, Seo H, et al. Degradation of the BAF complex factor BRD9 by heterobifunctional ligands. *Angew Chem Int Ed*. 2017;56:5738–43.
41. Theodoulou NH, Bamborough P, Bannister AJ, Becher I, Bit RA, Che KH, et al. Discovery of I-BRD9, a selective cell active chemical probe for bromodomain containing protein 9 inhibition. *J Med Chem*. 2016;59:1425–39.
42. Baliakas P, Hadzidimitriou A, Sutton LA, Minga E, Agathangelidis A, Nichelatti M, et al. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. *Lancet Haematol*. 2014;1:e74–84.
43. Stamatopoulos K, Agathangelidis A, Rosenquist R, Ghia P. Antigen receptor stereotypy in chronic lymphocytic leukemia. *Leukemia*. 2017;31:282–91.
44. Michel BC, D'Avino AR, Cassel SH, Mashtalir N, McKenzie ZM, McBride MJ, et al. A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation. *Nat Cell Biol*. 2018;20:1410–20.
45. Stark C, Breitkreutz B-J, Reguly T, Boucher L, Breitkreutz A, Tyers M. BioGRID: a general repository for interaction datasets. *Nucleic Acids Res*. 2006;34:D535–9.
46. Del Gaudio N, Di Costanzo A, Liu NQ, Conte L, Migliaccio A, Vermeulen M, et al. BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition. *Cell Death Dis*. 2019;10:338.
47. Beekman R, Chapaprieta V, Russiñol N, Vilarrasa-Blasi R, Verdaguier-Dot N, Martens JHA, et al. The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia. *Nat Med*. 2018;24:868–80.
48. Shuai S, Suzuki H, Diaz-Navarro A, Nadeu F, Kumar SA, Gutierrez-Fernandez A, et al. The U1 spliceosomal RNA is recurrently mutated in multiple cancers. *Nature*. 2019;574:712–6.
49. Mashtalir N, D'Avino AR, Michel BC, Luo J, Pan J, Otto JE, et al. Modular organization and assembly of SWI/SNF family chromatin remodeling complexes. *Cell*. 2018;175:1272–88.e20.
50. ten Hacken E, Valentin R, Regis FFD, Sun J, Yin S, Werner L, et al. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. *JCI Insight* 2018;3:e121438.
51. Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, Martín-Subero JJ, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. *Nature*. 2015;526:519–24.
52. Wang X, Wang S, Troisi EC, Howard TP, Haswell JR, Wolf BK, et al. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors. *Nat Commun*. 2019;10:1881.
53. Edelmann J, Holzmann K, Tausch E, Saunderson EA, Jebaraj BMC, Steinbrecher D, et al. Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. *Haematologica*. 2020;105:1379–90.
54. Li JSZ, Miralles Fusté J, Simavorian T, Bartocci C, Tsai J, Karlseder J, et al. TZIP1: a telomere-associated protein involved in telomere length control. *Science* (1979). 2017;355:638–41.
55. Mansouri L, Grabowski P, Degerman S, Svenson U, Gunnarsson R, Cahill N, et al. Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients. *Am J Hematol*. 2013;88:647–51.
56. Navrkalova V, Young E, Baliakas P, Radova L, Sutton L-A, Plevova K, et al. ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres. *Haematologica*. 2016;101:e369–73.
57. Kämpjärvi K, Järvinen TM, Heikkinen T, Ruppert AS, Senter L, Hoag KW, et al. Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. *Oncotarget*. 2015;6:1884–8.
58. Sooraj D, Sun C, Doan A, Garama DJ, Dannappel MV, Zhu D, et al. MED12 and BRD4 cooperate to sustain cancer growth upon loss of mediator kinase. *Mol Cell*. 2022;82:123–39.e7.

ACKNOWLEDGEMENTS

We acknowledge all current and former members of our groups involved in collecting samples and associated data used in this study. This project was supported by funding for RR from the Swedish Cancer Society (22 2448 Pj 01 H), the Swedish Research Council (2020-02121), Region Stockholm (FoU-962423), and Radiumhemets Forskningsfonder (224083); for KS from the Hellenic Precision Medicine Network in Oncology, and the Horizon 2020 project Neoteric; for PG and LS from the Italian Ministry of Health under Ricerca Finalizzata 2018 (RF2018-12368321); for PG from AIRC under IG 2022 (ID 27566), AIRC under 5 per Mille 2018 (ID 21198), and AIRC under Accelerator Award 2019 (ID 24295); for SP and KP from the Czech Ministry of Health under the program for the conceptual development of research organization (FNBr 65269705) and the AZV project (NU21-08-00237), and the National Institute for Cancer Research under the EXCELES project (LX22NPO5102) funded by the European Union - Next Generation EU. Sequencing was performed by the SNP&SEQ Technology Platform in Uppsala. The facility is part of the National Genomics Infrastructure (NGI) Sweden and Science for Life Laboratory. The SNP&SEQ Platform is also supported by the Swedish Research Council and the Knut and Alice Wallenberg Foundation. Furthermore, we acknowledge the ENCODE Consortium and the ENCODE production laboratories that generated the ChIP-seq data of the K562 cell line. The computations and data handling was enabled by resources provided by the Swedish National Infrastructure for Computing (SNIC) at Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) partially funded by the Swedish Research Council (2018-05973).

AUTHOR CONTRIBUTIONS

DH, BO, DC, KS, LAS, and RR designed the study; DH, BO, DC, YQ, ABP, CÖ, TDPS, LR, HFA, AS, VL, AL, ZH, CJ, JM, LM, LO, MV, KB, LAS, and RR performed research and interpreted results; MK contributed vital new reagents; KP, AA, LS, MA, AM, LM, NEK, TS, DR, SP, FD, AWL, PG, and KS provided samples and collected clinical data; DH, BO, ABP, LR, HFA, AS, LO, MV, and KB performed statistical analysis. DH, BO, JL, KS, LAS, and RR summarized and wrote the paper. All authors edited and approved the paper for submission.

FUNDING

Open access funding provided by Karolinska Institute.

COMPETING INTERESTS

NEK advisory board: AbbVie, AstraZeneca, BeiGene, Behring, Cytomx Therapy, Dava Oncology, Janssen, Juno Therapeutics/Celgene, ONCotracker, Pharmacyclics, and

Targeted Oncology; research funding: AbbVie, Acerta Pharma/AstraZeneca, Bristol Meyer Squib, Celgene, Genentech, MEI Pharma, Pharmacyclics, Sunesis, TG Therapeutics, and Tolero Pharmaceuticals. AWL honoraria: Janssen and Roche. PG honoraria/advisory board: AbbVie, Acerta Pharma/AstraZeneca, Adaptive, ArQule/MSD, BeiGene, Juno Therapeutics/Celgene, Gilead, Janssen, Loxo Oncology/Lilly, and Sunesis; research funding: AbbVie, Gilead, Janssen, Novartis, and Sunesis. KS honoraria: Janssen, Abbvie, and AstraZeneca; research funding: Janssen, Gilead Sciences, and AbbVie. LAS honoraria: AbbVie and Janssen. RR honoraria: AbbVie, AstraZeneca, Janssen, Illumina, and Roche. The other authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41375-024-02379-4>.

Correspondence and requests for materials should be addressed to Richard Rosenquist.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024